{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 458271727
| drug_name         =
| INN               =
| type              = <!-- empty -->
| image             = Toujeo 300 IU-ml inj.jpg
| width             =
| alt               =
| caption           = 인슐린 글라진 상품인 투제오(Toujeo)

<!-- Clinical data -->
| pronounce         =
| tradename = Lantus, Toujeo, Basaglar, 그 외
| Drugs.com = {{drugs.com|monograph|insulin_glargine}}
| MedlinePlus = a600027
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = yes
| DailyMedID        = Insulin_glargine
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = B3<ref name="Drugs.com pregnancy">{{웹 인용| title=Insulin glargine Use During Pregnancy | website=Drugs.com | date=6 April 2020 | url=https://www.drugs.com/pregnancy/insulin-glargine.html | access-date=4 September 2020 | archive-date=21 October 2020 | archive-url=https://web.archive.org/web/20201021163744/https://www.drugs.com/pregnancy/insulin-glargine.html | url-status=live }}</ref>
| pregnancy_category=
| routes_of_administration = [[피하 주사]]
| class             =
| ATCvet            =
| ATC_prefix = A10
| ATC_suffix = AE04
| ATC_supplemental  =
| biosimilars = insulin glargine-aglr, insulin glargine-yfgn, Rezvoglar, Abasaglar, Semglee

<!-- Legal status -->
| legal_AU = S4
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_CA = Rx-only/{{nbsp}}Schedule D<ref>{{웹 인용| title=Summary Basis of Decision - Semglee | website=Health Canada | date=23 August 2022 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00600&lang=en | access-date=29 September 2022 | archive-date=29 September 2022 | archive-url=https://web.archive.org/web/20220929045655/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00600&lang=en | url-status=live }}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = POM<ref>{{웹 인용| title=Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC) | website=(emc) | url=https://www.medicines.org.uk/emc/product/2376/smpc | access-date=7 May 2020 | archive-date=9 January 2021 | archive-url=https://web.archive.org/web/20210109065757/https://www.medicines.org.uk/emc/product/2376/smpc | url-status=live }}</ref>
| legal_US = Rx-only<ref>{{웹 인용| title=Lantus- insulin glargine injection, solution Lantus SoloStar- insulin glargine injection, solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a | access-date=29 July 2021 | archive-date=29 July 2021 | archive-url=https://web.archive.org/web/20210729050000/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a | url-status=live }}</ref>
| legal_EU          = Rx-only<ref>{{웹 인용| title=Lantus EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lantus | access-date=28 July 2021 | archive-date=4 August 2020 | archive-url=https://web.archive.org/web/20200804155233/https://www.ema.europa.eu/en/medicines/human/EPAR/lantus | url-status=live }}</ref><ref>{{웹 인용| title=Toujeo EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/toujeo-previously-optisulin | access-date=28 July 2021 | archive-date=29 July 2021 | archive-url=https://web.archive.org/web/20210729050012/https://www.ema.europa.eu/en/medicines/human/EPAR/toujeo-previously-optisulin | url-status=live }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_status      = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound     =
| metabolism =
| metabolites       =
| onset       = ~1시간<ref name=AHFS2018/>
| elimination_half-life =
| duration_of_action = 24~36시간<ref name=AHFS2018/>
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 160337-95-1
| CAS_supplemental  =
| PubChem           =
| IUPHAR_ligand = 7572
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00047
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 2ZM8CX04RZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03250
| ChEBI_Ref         =
| ChEBI             =
| ChEMBL_Ref        =
| ChEMBL            =
| NIAID_ChemDB      =
| PDB_ligand        =
| synonyms          = 

<!-- Chemical and physical data -->
| IUPAC_name = Recombinant human insulin
| C=267 | H=404 | N=72 | O=78 | S=6
| SMILES            =
| Jmol              =
| StdInChI          =
| StdInChI_comment  =
| StdInChIKey       =
| density           =
| density_notes     =
| melting_point     =
| melting_high      =
| melting_notes     =
| boiling_point     =
| boiling_notes     =
| solubility        =
| sol_units         =
| specific_rotation =
}}
'''인슐린 글라진'''({{llang|en|insulin glargine}})은 지속형 [[인슐린 유사체]]의 일종이다. 인슐린의 21번 [[글라이신]]을 [[아르기닌]]으로 치환하고 [[C-말단]]에 아르기닌을 두 개 추가하였다. 단백질 마이크로 크리스탈 형태로 [[피하 주사]]되어서 서서히 녹아 나오면서 기초 인슐린 분비를 보충해 준다. 식사 때는 필요하면 [[설포닐우레아]] 같은 경구용 인슐린 분비 촉진제를 함께 쓴다. 24시간 유지되기 때문에 하루에 한번 피하 주사한다.

== 같이 보기 ==
* [[인슐린]]

== 각주 ==
{{각주}}

{{토막글|생물학}}

[[분류:펩타이드 호르몬]]
[[분류:재조합 단백질]]
[[분류:세계 보건 기구 필수 의약품]]
[[분류:인슐린 치료]]
[[분류:인슐린 수용체 작용제]]